Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Vacancy: Postdoctoral Research Scientist – Statistics
10 March 2026
Professor Xin Lu featured on EACR’s The Cancer Researcher podcast
23 February 2026
Publications
-
Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.
Journal article
Makker J. et al, (2026), Haematologica, 111, 1096 - 1099
-
The Role of Fibroblast–Epithelial Cross-Talk on the Distribution of Distinct Fibroblast Phenotypes in the Intestinal Crypt
Journal article
Atkinson G. et al, (2026), Bulletin of Mathematical Biology, 88
-
Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease in a Cohort of Patients With Chronic Hepatitis B
Journal article
Kalafateli M. et al, (2026), Clinical Gastroenterology and Hepatology, 24, 701 - 712.e8
Seminars
conference
